Abstract

Rituximab-venetoklax ve druhé linii léčby chronické lymfocytární leukemie u pacienta s mutací TP53

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call